Join to View Full Profile
4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 904-953-2000
Dr. Chanan-Khan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Asher Chanan-Khan is an oncologist in Jacksonville, FL and is affiliated with Mayo Clinic Hospital in Florida. He received his medical degree from Allama Iqbal Medical College and has been in practice 24 years. He also speaks multiple languages, including Punjabi, Hindi, and Urdu. He specializes in hematologic oncology and is experienced in CLL, Waldenstrom Macroglobulinemia, hematologic oncology, and multiple myeloma.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1998 - 1999
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 1998
Harlem Hospital CenterResidency, Internal Medicine, 1994 - 1997
Allama Iqbal Medical CollegeClass of 1993
Certifications & Licensure
FL State Medical License 2011 - 2028
NY State Medical License 2002 - 2023
NJ State Medical License 1998 - 2003
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Access Profiler Enterprise, EMRConnect, 2014-2017
- CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2014-2017
Clinical Trials
- Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma Start of enrollment: 2004 Aug 01
- Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders Start of enrollment: 2005 Aug 01
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2005 Apr 01
Publications & Presentations
PubMed
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guide...Sameer A Parikh, Paul J Hampel, Lindsey E Roeker, Yucai Wang, Mazie Tsang
Mayo Clinic Proceedings. 2026-06-05 - A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.Ricardo D Parrondo, Sikander Ailawadhi, Betsy R Knopf, Ashley Zimmerman, Carly J Kasik
Blood Cancer Journal. 2026-05-07 - Multi-omics analysis reveals a unique epigenetic signature inwild-type Waldenström macroglobulinemia.Karan Chohan, Jonas Paludo, Surendra Dasari, Joseph P Novak, Jithma P Abeykoon
Haematologica. 2026-05-01
Abstracts/Posters
- Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based AnalysisAsher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS over 9 MonthsDecember 10th, 2024- Cellectar Biosciences : Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors (Form 8-K)June 25th, 2021
- Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of DirectorsJune 24th, 2021
Professional Memberships
- Member
- Member
Other Languages
- Punjabi, Hindi, Urdu
Industry Relationships
- Clinical Trial Principal Investigator, Jansen
- Clinical Trial Principal Investigator, Celgene
External Links
- Mayo Clinic Individualized Medicine Clinic for Cancerhttp://youtu.be/xVX-UL50tjo
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
